NCT02254031View on ClinicalTrials.gov

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 1, 2003

Primary Completion Date

January 1, 2005

Conditions
Breast Neoplasms
Interventions
DRUG

bivatuzumab mertansine

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02254031 - Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter